Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899459 | 1.00 | EPHX2 (0.38) | EPHX2MAPK1KDM1ALMNABLM | |
| SCHEMBL304611 | 1.00 | EPHX2 (0.38) | EPHX2MAPK1KDM1ALMNABLM | |
| SCHEMBL5211064 | 0.86 | MAPK1 (0.36) | EPHX2MAPK1KDM1ALMNABLM | |
| SCHEMBL1325109 | 0.82 | THRB (0.38) | LMNABLM | |
| SCHEMBL23183322 | 0.80 | EPHX2 (0.39) | EPHX2MAPK1KDM1ALMNABLM | |
| SCHEMBL17648648 | 0.80 | EPHX2 (0.39) | EPHX2MAPK1KDM1ALMNABLM | |
| SCHEMBL19122693 | 0.77 | EPHX2 (0.37) | EPHX2MAPK1KDM1ADDB1CRBN | |
| SCHEMBL27945905 | 0.75 | EPHX2 (0.38) | EPHX2MAPK1MEN1KMT2AGPR119 | |
| SCHEMBL28146558 | 0.71 | ALDH1A1 (0.37) | KDM1ABLMRECQLALDH1A1CYP3A4 | |
| SCHEMBL1202127 | 0.71 | ESR2 (0.41) | LMNABLMNR1H2NR1H3RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280970-B1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8124636-B2 | Imidazolidinone derivatives as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2118111-B1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | PFIZER (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2008059368-A2 | FUSED 2-AMINO PYRIMIDINE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008053319-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1879863-A1 | AMIDE RESORCINOL COMPOUNDS | Pfizer, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| EP-1773821-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060252778-A1 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | MERCK SHARP & DOHME CORP. | 2006-11-09 | — | — | US | disclosed |
| WO-2006117669-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | EPHX2 727/4885MAPK1 2340/4885KDM1A 3134/4885 |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | EPHX2 3386/4885MAPK1 1211/4885KDM1A 3625/4885 |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | EPHX2 3298/4885MAPK1 2149/4885KDM1A 3561/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | EPHX2 519/4885MAPK1 2191/4885KDM1A 3075/4885 |
| US-20060252778-A1 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | ADAM17, ADAMTS1, ADAM10 | EPHX2 621/4885MAPK1 2607/4885KDM1A 1395/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | EPHX2 639/4885MAPK1 979/4885KDM1A 3701/4885 |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | HSP90AB2P, HSP90AB1, HSP90AA1 | EPHX2 2581/4885MAPK1 1703/4885KDM1A 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.